These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35974705)

  • 21. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
    Queiro Silva R; Armesto S; González Vela C; Naharro Fernández C; González-Gay MA
    Dermatol Ther; 2020 Nov; 33(6):e13961. PubMed ID: 32618402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
    Gisondi P; Girolomoni G
    Drug Des Devel Ther; 2016; 10():1763-70. PubMed ID: 27307707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical and Oral Roflumilast in Dermatology: A Narrative Review.
    Mansilla-Polo M; Gimeno E; Morgado-Carrasco D
    Actas Dermosifiliogr; 2024 Mar; 115(3):265-279. PubMed ID: 37709133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections.
    Manfreda V; Esposito M; Campione E; Bianchi L; Giunta A
    Postgrad Med; 2019 Apr; 131(3):239-240. PubMed ID: 30700196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on the safety of apremilast for the treatment of plaque psoriasis.
    Shavit E; Shear NH
    Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
    [No Abstract]   [Full Text] [Related]  

  • 28. Analytical Methods for Determination of Apremilast from Bulk, Dosage Form and Biological Fluids: A Critical Review.
    Kulkarni P; Deshpande A
    Crit Rev Anal Chem; 2021; 51(3):258-267. PubMed ID: 32024370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psoriatic patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks.
    Bernardini N; Skroza N; Marchesiello A; Mambrin A; Proietti I; Tolino E; Maddalena P; Marraffa F; Rossi G; Volpe S; Potenza C
    Dermatol Ther; 2022 Oct; 35(10):e15306. PubMed ID: 35100460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
    Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
    Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apremilast and biologics: Characteristics of patients treated with apremilast before, during, or after a biological treatment.
    Pinto-Pulido EL; Lario AR; Vega-Díez D; González-Cañete M; García-Verdú E; Polo-Rodríguez I; Piteiro-Bermejo AB; Medina-Montalvo S; Trasobares-Marugán L
    Dermatol Ther; 2022 Nov; 35(11):e15844. PubMed ID: 36124339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apremilast and its role in psoriatic arthritis.
    Sandhu VK; Eder L; Yeung J
    G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
    Haber SL; Hamilton S; Bank M; Leong SY; Pierce E
    Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Gastrointestinal side effects of apremilast : Characterization and management].
    Pinter A; Beigel F; Körber A; Homey B; Beissert S; Gerdes S; Staubach-Renz P; Radtke MA; Mössner R
    Hautarzt; 2019 May; 70(5):354-362. PubMed ID: 30937481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
    Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
    G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.